1. Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.
- Author
-
Bugia L, Jungbauer F, Zaubitzer L, Hörner C, Merx K, Yasser AM, Germann T, Lammert A, Scherl C, Rotter N, and Affolter A
- Subjects
- Humans, Male, Aged, Salivary Gland Neoplasms drug therapy, Salivary Gland Neoplasms therapy, Salivary Gland Neoplasms diagnosis, Salivary Gland Neoplasms pathology, Salivary Ducts pathology, Treatment Outcome, Carcinoma, Ductal therapy, Carcinoma, Ductal drug therapy, Carcinoma, Ductal diagnosis, Neoplasm Metastasis, Antineoplastic Agents, Immunological therapeutic use, Lung Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms diagnosis, Lung Neoplasms therapy, Nivolumab therapeutic use
- Abstract
Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF